Investing.com - Regeneron Pharma (NASDAQ:REGN) reported third quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.
The firm reported earnings per share of $6.67 on revenue of $2.05B. Analysts polled by Investing.com anticipated EPS of $6.41 on revenue of $1.99B. That compared to EPS of $5.87 on revenue of $1.66B in the same period a year earlier. The company had reported EPS of $6.02 on revenue of $1.93B in the previous quarter.
For the year, Regeneron Pharma shares are down 16.72%, under-performing the Nasdaq which is up 29.6% year to date.
Regeneron Pharma follows other major Healthcare sector earnings this month
On Tuesday, October 15, 2019, J&J reported third quarter EPS of $2.12 on revenue of $20.73B, compared to forecasts of EPS of $2.01 on revenue of $20.08B.
Merck&Co earnings beat analyst's expectations on Tuesday, October 29, 2019, with third quarter EPS of $1.51 on revenue of $12.4B. Investing.com analysts expected EPS of $1.24 on revenue of $11.64B
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar